Like many cancers, mantle cell lymphoma can vary in how quickly it develops and its severity. As Szubanski's cancer has been described as "fast-moving" and is already stage 4, it appears that it ...

Everyone treating mantle cell lymphoma agrees that BTK inhibitors have a role, ... Notably, there is an increased incidence of cardiovascular adverse events associated with ibrutinib, ...

Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin’s lymphoma (NHL), a cancer that develops in the lymphatic system. The lymphatic system helps to protect the body from infection.

Mantle cell lymphoma (MCL) is a rare cancer affecting the lymphatic system. It shares characteristics with other types of lymphomas, but understanding the signs and symptoms of MCL can help a ...

Mantle cell lymphoma is a rare and aggressive form of non-Hodgkin's lymphoma. Diagnosis typically involves a physical exam, biopsies, genetic screening, and antigen testing.

SAN DIEGO — Mantle cell lymphoma patients who go into deep remission from a first therapy may not get any benefit from a follow-up transplant of their stem cells, according to a new study.

The ECHO trial's international scope, spanning 27 countries, underscores the global effort to improve treatment for this aggressive form of non-Hodgkin lymphoma.

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent ...

AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an ...

Mantle cell lymphoma is a rare, aggressive type of non-Hodgkin lymphoma arising from malignant B cells in the mantle zone of lymph nodes. It accounts for about 5% of lymphoma cases, is more common ...